Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akcea Expects Convenience Edge For Tegsedi, Despite Monitoring Requirements

Executive Summary

Approved two months after Alnylam’s Onpattro, Tegsedi is priced almost identically in the same hATTR indication. Ionis affiliate Akcea hopes weekly subcutaneous administration will provide convenience benefit compared to I.V. Onpattro.

Advertisement

Related Content

Ionis Catches The Eye With New Roche Alliance
Complete Response Letters See Uptick With US FDA's Thumbs Down For Waylivra
Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro
As Gilead Seeks New CEO, Second Quarter Shows Stability
Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123968

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel